Oncology Clinical Trials in Boston, MA
As of September 2026, 613 paid clinical trials are recruiting for Oncology in Boston, Massachusetts. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Boston
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
615 clinical trials for Oncology
·Clear filters·A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Top Research Study Locations in Boston
Researchers run research studies in Boston, MA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Massachusetts General Hospital | Breast Cancer, Advanced Solid Tumor, Heart Failure | 693 |
| Brigham and Women's Hospital | Obesity, Breast Cancer, Prostate Cancer | 352 |
| Dana-Farber Cancer Institute | Breast Cancer, Acute Myeloid Leukemia, Multiple Myeloma | 346 |
| Beth Israel Deaconess Medical Center | Multiple Myeloma, Lymphoma, Acute Myeloid Leukemia | 263 |
| Boston Children's Hospital | Congenital Heart Disease, Cystic Fibrosis, Sickle Cell Disease | 258 |
| Dana Farber Cancer Institute | Breast Cancer, Ovarian Cancer, Prostate Cancer | 218 |
| Tufts Medical Center | Heart Failure, Acute Myeloid Leukemia, Acute Respiratory Distress Syndrome | 113 |
| Boston Medical Center | Amblyopia, Alpha1-Antitrypsin Deficiency, Anatomic Stage II Breast Cancer AJCC v8 | 95 |
| Massachusetts General Hospital Cancer Center | Breast Cancer, Coping Skills, B Acute Lymphoblastic Leukemia | 51 |
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | Chronic Obstructive Pulmonary Disease, Mild Traumatic Brain Injury, Prostate Cancer | 30 |
| Brigham & Women's Hospital | Attention, Chronic Lymphocytic Leukemia, Critical Illness | 25 |
| Boston University | Obsessive-Compulsive Disorder, Adolescent Behavior Problem, Alzheimer Disease | 24 |
| Joslin Diabetes Center | Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), T1D | 22 |
| Mass General Brigham | Heart Failure, Heart Failure With Preserved Ejection Fraction, Advanced Solid Tumors | 22 |
| Northeastern University | Cognitive Change, Autism Spectrum Disorder (ASD), Healthy | 22 |
| Massachusetts Eye and Ear | Cone Rod Dystrophy, Glaucoma, Juvenile Macular Degeneration | 17 |
| Ophthalmic Consultants of Boston | Neovascular Age-related Macular Degeneration, Macular Edema Secondary to Inflammation, Age-Related Macular Degeneration | 13 |
| Adams Clinical Boston | Depressive Disorder, Major, Major Depressive Disorder, Alcohol Use Disorder | 12 |
| Brigham and Womens Hospital | Advanced Prostate Cancer, Alpha1-Antitrypsin Deficiency, Alzheimers Disease | 12 |
| Massachusetts Eye and Ear Infirmary | Laryngeal Dystonia, Stargardt Disease, Age-related Macular Degeneration | 12 |
| Clinical Trial Site | Transthyretin Amyloidosis With Cardiomyopathy, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency | 11 |
| Boston Childrens Hospital | CSTB-related Disease, Crohn's Disease, Cystic Fibrosis | 11 |
| Mass General Hospital | Biliary Tract Cancer (BTC), PDAC - Pancreatic Ductal Adenocarcinoma, AML | 11 |
| Beth Israel Deaconess Medical Center (BIDMC) | Prostate Cancer, Advanced Melanoma, Endometrial Cancer | 9 |
| Brigham and Women's Faulkner Hospital | Multimodal Analgesia, Opioid Consumption, Postoperative, Adverse Event | 8 |
Active & Upcoming Studies in Boston (2026)
Recruiting trials in Boston grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (879 active studies)
- Early Intervention · Massachusetts General Hospital
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) · Phase 2 · National Cancer Institute (NCI)
Neurology & pain (218 active studies)
- Mindfulness Therapy for Chronic Pain After Intimate Partner Violence · Brigham and Women's Hospital
- Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · Brigham and Women's Hospital
Cardiovascular (187 active studies)
- Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · Brigham and Women's Hospital
- CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock · Phase 2 · Brigham and Women's Hospital
Diabetes & metabolic (97 active studies)
- Adiposity Distribution in Acute Respiratory Failure · Maurizio F. Cereda, MD
- Creating Linked Inpatient CGM for Kids · Boston Children's Hospital
Mental health & behavior (90 active studies)
- Whole Selves User Testing and Feasibility Study · Boston University
- Clinician Practice Companion to Address Youth Substance Use · Massachusetts General Hospital
Pediatric (63 active studies)
- Clinician Practice Companion to Address Youth Substance Use · Massachusetts General Hospital
- Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors · Dana-Farber Cancer Institute
HIV / STI (33 active studies)
- Intervention to Reduce Implicit Bias in Pharmacies · Massachusetts General Hospital
- Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · Boston Children's Hospital
Eye & vision (32 active studies)
- Glaucoma Drop Aids Part 2 · Boston Medical Center
- Study of Remimazolam for Cataract Surgery · Phase 4 · Fred E, Shapiro
Vaccines (15 active studies)
- Sauna for Long Covid · Massachusetts General Hospital
- A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Common conditions studied in Boston
- Breast Cancer (64 active studies)
- Prostate Cancer (41 active studies)
- Ovarian Cancer (36 active studies)
- Heart Failure (34 active studies)
- Acute Myeloid Leukemia (32 active studies)
- Colorectal Cancer (32 active studies)
Leading research sponsors in Boston
- Massachusetts General Hospital
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Boston Children's Hospital
- Beth Israel Deaconess Medical Center
Frequently asked questions
How many paid clinical trials are currently recruiting in Boston?
There are approximately 2,894 recruiting clinical trials in Boston, Massachusetts listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Boston pay participants?
Most recruiting trials in Boston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Boston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Boston?
The most common conditions under active study in Boston include Breast Cancer (64), Prostate Cancer (41), Ovarian Cancer (36), Heart Failure (34), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Boston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Boston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Boston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Boston?
Recruiting research sites in Boston include Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Boston right now?
The largest active categories in Boston are Cancer & tumors (879), Neurology & pain (218), Cardiovascular (187). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.